Four more listed companies were added to the "impact of the epidemic", and the performance of the fourth quarter was affected

Reporter | Chen Huidong

Edit |

1

With the continuous fermentation of the epidemic in Jiangsu and Zhejiang, a number of local listed companies have disclosed the announcement of suspension of production.

On December 13, Yantu Shares (002440. SZ), Mustang Battery (605373. SH), Guobang Pharmaceutical (605507. SH), Ningbo Fubon (600768. SH) and four other listed companies in Zhejiang have issued announcements of suspension of production due to the impact of the epidemic.

So far, according to incomplete statistics, since December 2021, there have been 21 listed companies that have announced the suspension of production due to the epidemic in Zhejiang, and most of them are companies with registered places or subsidiaries in Shaoxing Shangyu.

According to ningbo Fubon's announcement on December 13, Ningbo Fubon Precision Aluminum Profile Co., Ltd. (hereinafter referred to as "Fubon Precision"), a wholly-owned subsidiary of the company, has recently implemented an orderly suspension of production as required in order to cooperate with the prevention and control of the new crown epidemic. The suspension is expected to have a certain impact on the Company's operating results for the fourth quarter of 2021.

Ningbo Fubon registered place is located in Zhenhai District, Ningbo City, the company's main business belongs to the non-ferrous metal rolling processing industry, is a professional production of industrial aluminum profiles of regional aluminum deep processing enterprises, concurrently engaged in aluminum casting rod products and other trade business. Fubon Precision is one of the core subsidiaries of the listed company, achieving revenue of 29.0383 million yuan and net profit of 718,400 yuan in 2020 (during the same period, the revenue of listed companies was 495 million yuan and the net loss was 6.066 million yuan).

Ningbo Fubon's aluminum profile processing and aluminum trading business existing scale belongs to the small and medium level, in 2020, the company's main production equipment is aging, product structure is traditional, and by the macroeconomic environment and changes in the market environment under the new crown epidemic, the gross profit margin level is low, the overall profitability is insufficient. In the first three quarters of this year, the company achieved a year-on-year decline in revenue of 4.32% to 326 million yuan; the net profit attributable to shareholders of listed companies fell by 49.98% year-on-year to 990,500 yuan.

On December 13, Yantu Co., Ltd. announced that the company actively responded to the government's epidemic prevention policy, and all subsidiaries located in the Shangyu Economic and Technological Development Zone in Hangzhou Bay, Zhejiang Province, began to stop feeding on the afternoon of December 9 and gradually stopped production. All of the Company's subsidiaries in the Shangyu Economic and Technological Development Zone in Hangzhou Bay, Zhejiang Province, mainly produce dyes, additives and chemical raw materials, accounting for about 95% of the operating income from January to September 2021 (unaudited). The suspension of production will have a certain adverse impact on the company's operating results in the fourth quarter of 2021.

Located in Shangyu District, Shaoxing City, Yantu Co., Ltd. is mainly engaged in the research and development, production and sales of textile dyes, printing and dyeing auxiliaries and chemical raw materials. In 2020, the company's revenue fell by 19.73% year-on-year to 5.228 billion yuan; net profit attributable to shareholders of the parent company fell by 42.47% year-on-year to 788 million yuan, and the company attributed the sharp decline in performance to the delay in the resumption of work of the company and downstream textile printing and dyeing enterprises after the epidemic, and the company's normal production and operation activities were affected; textile and garment exports were hit, downstream textile printing and dyeing enterprises lacked confidence, the company's main product prices were weak, and prices and sales fell year-on-year.

In the first three quarters of this year, The revenue of Yantu Shares increased by 16.33% year-on-year to 4.251 billion yuan, and the net profit attributable to the shareholders of the parent company increased by 20.10% year-on-year to 669 million yuan.

Mustang Battery announced on December 13 that the company was temporarily suspended in an orderly manner due to the impact of the epidemic. It is expected that this orderly temporary shutdown will delay the production and delivery of some of the company's products, which is expected to adversely affect the company's operating results this month.

Mustang Battery is located in Zhenhai District, Ningbo City, officially landed on April 12 this year A shares, the company is mainly engaged in high-performance, environmentally friendly zinc-manganese battery research and development, production and sales. In the first three quarters of this year, the company achieved revenue increased by 10.15% year-on-year to 899 million yuan; net profit attributable to shareholders of the parent company fell by 27.61% year-on-year to 0.65 billion yuan.

According to the announcement of Guobang Pharmaceutical on December 13, zhejiang guobang and zhejiang dongying, wholly-owned subsidiaries, have temporarily stopped production in an orderly manner due to the impact of the epidemic, and the resumption time will be arranged according to the requirements of the local government. In addition, the company's other production bases are operating normally. Zhejiang Guobang and Zhejiang Dongying mainly produce macrolides, quinolones, and cephalosporin APIs, and the operating income and proportion in the 1-3 quarters of 2021 (unaudited) are as follows:

Image source: Announcement

Guobang Pharmaceutical said that it is expected that the orderly temporary suspension of production will delay the production and delivery of some of the company's products, which will have a certain adverse impact on the company's operating performance this month, but the impact on the company's overall performance in 2021 is relatively limited.

Guobang Pharmaceutical was established in 1996 and officially landed on A shares on August 2 this year. The company is mainly engaged in the research and development, production and sales of related products in the field of medicine and animal health products, and its traditional Chinese medicine sector covers APIs, key pharmaceutical intermediates and preparations, and animal health products covers animal protection APIs, animal protection additives and preparations.

The prospectus shows that Zhejiang Guobang, which has stopped production this time, is a core subsidiary of a listed company. In 2020, Zhejiang Guobang achieved a net profit of 391 million yuan (accounting for about 48% of the total net profit of listed companies).

In the first three quarters of this year, Guobang Pharmaceutical achieved revenue increased by 2.12% year-on-year to 3.213 billion yuan; net profit attributable to shareholders of the parent company fell by 18.23% year-on-year to 521 million yuan.

According to interface news, on December 9, the leading group for the prevention and control of the new coronavirus pneumonia epidemic in Shangyu District, Shaoxing City, issued the "Notice on Comprehensively Strengthening Control Measures in the Whole District", requiring that "except for the needs of epidemic prevention and people's livelihood protection, all other enterprises will stop work".

At the same time, the Leading Group for the Prevention and Control of the Novel Coronavirus Pneumonia Epidemic in Zhenhai District, Ningbo City, also issued the Notice on Comprehensively Strengthening Control Measures in the Whole Region, requiring all enterprises in the region to stop work except for epidemic prevention needs and people's livelihood protection.